


A case for routine evaluation of HER2 expression in ductal carcinoma in situ

February 17 2023



Credit: Unsplash/CC0 Public Domain

A new editorial paper was published in *Oncoscience* and is titled "HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!"

HER2 is more frequently overexpressed in [ductal carcinoma](#) in situ (DCIS) than in [invasive breast cancer](#). However, unlike invasive cancer, HER2 is not routinely evaluated in DCIS. In this new editorial, researchers Nidhi Garg and Mangesh A. Thorat from Guy's and St Thomas' NHS Foundation Trust, Wolfson Institute of Population Health, Queen Mary University of London, and King's College London discussed their recent study, which they claim is the largest biomarker study in a DCIS randomized trial.

"Prior to our study, just about a third of studies (10 of 27) investigating the association between HER2 overexpression and [recurrence risk](#) reported a significant association," note the researchers.

They showed that HER2 overexpression was associated with a 2-fold higher ipsilateral breast event (IBE) risk mediated through almost 3-fold higher ipsilateral in situ event (DCISIBE) risk [Hazard ratio (HR) = 2.90; 95% CI, 1.91–4.40; p

"In this comment, we discuss the significance and clinical implications of these results. We also hope to convince the reader that more robust data are unlikely to be available for a foreseeable future and therefore [clinical practice](#) needs to change based on these results and start routinely evaluating HER2 to prevent under or overtreatment of DCIS patients," state the researchers.

More information: Nidhi Garg et al, HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!, *Oncoscience* (2023). [DOI: 10.18632/oncoscience.572](https://doi.org/10.18632/oncoscience.572)

Mangesh A. Thorat et al, Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial, *Clinical Cancer Research* (2021). [DOI:](#)

[10.1158/1078-0432.CCR-21-1239](https://doi.org/10.1158/1078-0432.CCR-21-1239)

Provided by Impact Journals

Citation: A case for routine evaluation of HER2 expression in ductal carcinoma in situ (2023, February 17) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-02-case-routine-her2-ductal-carcinoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.